INITIAL REPORT OF PART B PHASE 1/2 EFFICACY AND SAFETY RESULTS FOR BRUTON TYROSINE KINASE INHIBITOR RILZABRUTINIB IN PATIENTS WITH RELAPSED IMMUNE THROMBOCYTOPENIA

被引：0
|
作者：
Cooper, Nichola [1 ]
Jansen, A. J. Gerard [2 ]
Mayer, Jiri [3 ]
Tarantino, Michael D. [4 ]
Diab, Remco [5 ]
Ward, Brad [6 ]
Daak, Ahmed [6 ]
Kuter, David J. [7 ]
机构：
[1] Hammersmith Hosp, London, England
[2] Univ Med Ctr, Erasmus MC, Rotterdam, Netherlands
[3] Masaryk Univ Hosp, Brno, Czech Republic
[4] Univ Illinois, Bleeding & Clotting Disorders Inst, Coll Med Peoria, Peoria, IL USA
[5] Sanofi, Rotkreuz LU, Vernier, Switzerland
[6] Sanofi, Cambridge, MA USA
[7] Harvard Med Sch, Massachusetts Gen Hosp, Div Hematol, Boston, MA 02115 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [21] Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study
    Tam, Constantine S.
    Frustaci, Anna Maria
    Bijou, Fontanet
    Zinzani, Pier Luigi
    Seymour, John F.
    Lasica, Masa
    Eradat, Herbert A.
    Lin, Victor T. G.
    Alwan, Maan
    Mocanu, Irina
    Chen, Xiangmei
    By, Kunthel
    Fabre, Shannon
    Persky, Daniel O.
    Agarwal, Amit
    Cheah, Chan Y.
    BLOOD, 2024, 144 : 1649 - 1650
  • [22] Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with WaldenstrC6m Macroglobulinemia from a Phase 2 Trial
    An, Gang
    Zhou, Daobin
    Zhao, Weili
    Zhou, Keshu
    Li, Jianyong
    Zhou, Jianfeng
    Xie, Liping
    Jin, Jie
    Zhong, Liye
    Yan, Lingzhi
    Guo, Haiyi
    Du, Chenmu
    Huang, Jane
    Novotny, William
    Zhong, Jinhua
    Qiu, Lugui
    BLOOD, 2020, 136
  • [23] Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and NonCovalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Song, Yuqin
    Cai, Qingqing
    Jiang, Ming
    Zhou, Keshu
    Zhang, Lei
    Sun, Xiuhua
    Jin, Zhengming
    Li, Lanfang
    Jing, Hongmei
    Peng, Zhigang
    Yang, Haiyan
    Qi, Junyuan
    Zhou, Hui
    Yang, Wei
    Zhou, Min
    Ji, Chunyan
    Xu, Wei
    Ding, Kaiyang
    Yu, Li
    Wang, Zheng
    Liu, Nawei
    Lou, Yejiang
    Shen, Yue
    Chen, Yi
    Tan, Fenlai
    Zhu, Jun
    BLOOD, 2023, 142
  • [24] Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial
    Mease, Philip
    Helliwell, Philip S.
    Silwinska-Stanczyk, Paula
    Miakisz, Malgorzata
    Ostor, Andrew
    Peeva, Elena
    Vincent, Michael
    Sikirica, Vanja
    Winnette, Randall
    Qiu, Ruolun
    Li, Gang
    Feng, Gang
    Beebe, Jean
    Martin, David
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1009 - 1011
  • [25] The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
    Opat, Stephen
    Tedeschi, Alessandra
    Linton, Kim
    McKay, Pamela
    Hu, Bei
    Chan, Henry
    Jin, Jie
    Sobieraj-Teague, Magdalena
    Zinzani, Pier Luigi
    Coleman, Morton
    Thieblemont, Catherine
    Browett, Peter
    Ke, Xiaoyan
    Sun, Mingyuan
    Marcus, Robert
    Portell, Craig A.
    Ardeshna, Kirit
    Bijou, Fontanet
    Walker, Patricia
    Hawkes, Eliza A.
    Mapp, Sally
    Ho, Shir-Jing
    Talaulikar, Dipti
    Zhou, Ke-Shu
    Co, Melannie
    Li, Xiaotong
    Zhou, Wenxiao
    Cappellini, Massimo
    Tankersley, Chris
    Huang, Jane
    Trotman, Judith
    CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6323 - 6332
  • [26] SAFETY AND EFFICACY OF LY3337641, A BRUTON'S TYROSINE KINASE INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART PHASE 2 STUDY
    Genovese, Mark C.
    Spindler, Alberto
    Sagawa, Akira
    Park, Won
    Dudek, Anna
    Kivitz, Alan
    Chao, Jeannie
    Chan, Lai Shan
    Barchuk, William
    Nirula, Ajay
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1109 - 1110
  • [27] A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies
    Song, Yuqin
    Sun, Mingyuan
    Qi, Junyuan
    Xu, Wei
    Zhou, Jianfeng
    Li, Dengju
    Li, Jianyong
    Qiu, Lugui
    Du, Chenmu
    Guo, Haiyi
    Huang, Jane
    Tang, Zhiyu
    Ou, Ying
    Wu, Binghao
    Yu, Yiling
    Zhu, Jun
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (01) : 62 - 72
  • [28] Clinical Predictors of Response to Rilzabrutinib Therapy in Patients with Immune Thrombocytopenia: Exploratory Analysis of a Phase 1/2 Study
    Kuter, David J.
    Ghanima, Waleed
    Khan, Umer
    Li, Mengyao
    Shan, Jenny
    Daak, Ahmed
    Cooper, Nichola
    BLOOD, 2022, 140 : 5559 - 5561
  • [29] A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenstrom Macroglobulinemia
    An, Gang
    Zhou, Daobin
    Cheng, Shu
    Zhou, Keshu
    Li, Jianyong
    Zhou, Jianfeng
    Xie, Liping
    Jin, Jie
    Zhong, Liye
    Yan, Lingzhi
    Guo, Haiyi
    Du, Chenmu
    Zhong, Jinhua
    Yu, Yiling
    Wu, Binghao
    Qiu, Lugui
    CLINICAL CANCER RESEARCH, 2021, 27 (20) : 5492 - 5501
  • [30] What management in relapsed patients after inhibitors of Bruton's tyrosine kinase and B-cell lymphoma 2?
    Tournilhac, Olivier
    HEMATOLOGIE, 2020, 26 : 34 - 48
12345